CClinicalTrials.gg
CompletedNCT01123200Updated Mar 15, 2017Results posted

An In-home Study of Brain Computer Interfaces

An interventional study of Brain Computer Interface for Wheelchair Tilt Control in Amyotrophic Lateral Sclerosis, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by University of Michigan · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The investigators are developing a tool to help people who are severely paralyzed. This tool is called a brain-computer interface (BCI). BCIs can connect to computers or other electronic devices.

This study allows a person with ALS to communicate, control their wheelchair tilt and perform other tasks using a BCI, thus increasing their independence.

Read the detailed description

This small-scale study of the feasibility of a BCI to operate the tilt position of a power wheelchair was also designed to determine the conditions and support structures necessary for use of a BCI in the home. In this study, people with Amyotrophic Lateral Sclerosis (ALS) will have a BCI in their home. They will receive training in order to operate and maintain the BCI. The BCI will allow them to access at least one task of primary interest to them. Task may include communication, computer access, control of assistive technology, or control of wheelchair seat position. Data concerning the use of the BCI will be collected throughout the study. Custom installations will be made for each participant to connect to their wheelchair and provide communication options if needed. Each installation is expected to be a unique prototype because of the differing control requirements for the individual wheelchairs in use by the participants.

We intended to enroll six participants, but were only able to enroll one.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis
03

In context

Motor Neuron Disease

717 studies on the registry are indexed under Motor Neuron Disease; 137 are open to participants now.

This study's enrollment of 1 is below the median of 35 across 461 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 or older.
  • Presently having difficulty communicating or operating the controls for assistive technology or likely to have difficulty in the next six months.
  • Able to see the BCI display
  • Able to understand and remember instructions concerning participation.
  • Live in an environment that can accommodate the wheelchair portable BCI host computer
  • Expected to live in the same physical environment for at least 6 months.
  • Has family and caregiver(s) who are supportive of participation in this research.
  • Has a primary caregiver who is technically capable, willing to learn the setup and operation of the BCI system, and likely to remain with the subject for at least 6 months.
  • Has been shown to be able to use a BCI (in an experimental session under another IRB, e.g. HUM 00012968).
  • Has a clear understanding of the shortcomings of the present state of BCI technology

Exclusion criteria

Exclusion Criteria:

  • Open head lesions or a history of problems with skin breakdown on the head that may be aggravated by repeated application of electrodes.
  • Inability to communicate well enough to give informed consent.
  • History of photo-sensitive epilepsy
  • Known significant cognitive deficits
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Other
    Brain Computer Interface In-Home Use

    Device: Brain Computer Interface for Wheelchair Tilt Control

Interventions

  • DeviceBrain Computer Interface for Wheelchair Tilt Control

    Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.

06

What researchers measure

Primary outcomes

  1. Duration of BCI Usage by Persons With ALS.

    Number of months of BCI usage by each participant.

    Time frame: Monthly measurements for a period of up to 18 months.

Secondary outcomes

  1. Changes in Accuracy of BCI for Controlling Devices and Text

    Changes in Accuracy Percentage (i.e., cumulative correct selections per month divided by the cumulative number of intended sections per month). Looking for trends over each 6 month period.

    Time frame: 6 months, 12 months, 18 months

07

Results

Posted Mar 15, 2017

Participant flow

Participant flow — Overall Study
MilestoneBrain Computer Interface In-Home Use
Started1
Completed0
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryDuration of BCI Usage by Persons With ALS.

Number of months of BCI usage by each participant.

Time frame:
Monthly measurements for a period of up to 18 months.
Reported as:
Mean · months
Duration of BCI Usage by Persons With ALS.
monthsBrain Computer Interface In-Home Use
Duration of BCI Usage by Persons With ALS.5 (5 to 5)
SecondaryChanges in Accuracy of BCI for Controlling Devices and Text

Changes in Accuracy Percentage (i.e., cumulative correct selections per month divided by the cumulative number of intended sections per month). Looking for trends over each 6 month period.

Time frame:
6 months, 12 months, 18 months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brain Computer Interface In-Home Use—0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventBrain Computer Interface In-Home Use
Unexpected wheelchair movementProduct Issues1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brain Computer Interface In-Home Use
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Brain Computer Interface In-Home Use
Female0
Male1
Region of Enrollment
Region of Enrollment(participants)Brain Computer Interface In-Home Use
United States1
08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01123200
Lead sponsor
University of Michigan
Responsible party
Jane Huggins, PhD (Research Assistant Professor, University of Michigan) — Principal investigator
First posted
May 14, 2010
Start date
Jan 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Mar 15, 2017
Last update
Mar 15, 2017

Study contacts

Jane Huggins, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion